1. A computer system for detecting financial transactions by individual clients appropriate for review, the computer system comprising:
one or more data storage devices storing a list of excluded internal transaction types and financial transaction data for financial transactions by the individual clients;
one or more computer processors in communication with the one or more data storage devices;
a communications device in communication with the one or more computer processors and the one or more data storage devices; and
a memory, coupled to the one or more computer processors, storing program instructions which are operative with the one or more computer processors to:
receive one or more financial transactions;
compare each of the received financial transactions to the list of excluded internal transaction types;
determine, for each of the financial transactions, based on the comparison, whether the financial transaction is an excluded internal transaction;
responsive to a determination that the financial transaction is an excluded internal transaction, exclude the financial transaction from additional screening;
responsive to a determination that the financial transaction is not an excluded internal transaction:
determine whether a compilation of transactions already exists for transactions of the respective individual client;
responsive to a negative determination that the compilation of transactions already exists for the respective individual client, create the compilation of transactions for the respective individual client; and
add the financial transaction to the compilation of transactions for the respective individual client that performed the financial transaction, thereby compiling separate compilations of transactions for one or more of the individual clients from the financial transaction data, each compilation of transactions comprising financial transaction data related to a respective individual client;
compare, for each compilation of transactions, the external financial transactions in the compilation of transactions for the respective individual client, with at least one screening criterion for detecting a suspicious pattern of financial transaction activity by each respective individual client;
determine, based on the comparison, whether the compilation of transactions for the respective individual client includes financial transactions that match the at least one screening criterion; and
responsive to an affirmative determination that the compilation of transactions includes financial transactions that match the at least one screening criterion, add the compilation of transactions to a monitoring report; and
output the monitoring report for review.
2. The computer system of claim 1, wherein the list of excluded internal transaction types stored in the one or more data storage device includes systematic redemption transactions, dealer account transactions, omnibus account transactions, dividend transactions, capital gain transactions, and redemption transactions due to death of an account holder.
3. The computer system of claim 1, wherein the compilation of transactions for at least some of the respective individual clients includes a plurality of financial transactions, and the plurality of financial transactions collectively relate to a plurality of accounts related to the respective individual client for the each compilation of transactions.
4. The computer system of claim 1, wherein the at least one screening criterion includes one or both of a criterion based on (a) an aggregate monetary amount of all external financial transactions in a respective compilation of transactions for the individual client, and (b) an aggregate number of all external financial transactions within the screening time interval in the respective compilation of transactions for the individual client.
5. The computer system of claim 4, wherein the aggregate monetary amount is modified from time to time.
6. The computer system of claim 4, wherein the aggregate number of financial transactions is modified from time to time.
7. The computer system of claim 1, wherein the program instructions are further operative with the one or more computer processors to exclude selected external financial transactions.
8. The computer system of claim 1, wherein the program instructions being operative with the one or more computer processors to output the monitoring report for review comprises the program instructions being operative with the one or more computer processors to transmit, by the communication device, the monitoring report to an analyst computer for review.
9. The computer system of claim 1, wherein the at least one screening criterion comprises at least one screening for detecting a suspicious pattern of financial transaction activity by each respective individual client during a screening time interval.
10. A method of operating a computer system to identify one or more questionable financial transactions, the method comprising:
accessing, by one or more computer processors, a database of financial transaction data for one or more financial transactions from a data warehouse storage system;
comparing, by the one or more computer processors, each of the accessed financial transactions to a list of excluded internal transaction types;
determining, by the one or more computer processors, for each of the financial transactions, based on the comparison, whether the financial transaction is an excluded internal transaction;
responsive to a determination that the financial transaction is an excluded internal transaction, excluding, by the one or more computer processors, the financial transaction from additional screening;
responsive to a determination that the financial transaction is not an excluded internal transaction:
determining whether a compilation of transactions already exists for transactions of the respective individual client;
responsive to a negative determination that the compilation of transactions already exists for the respective individual client, creating the compilation of transactions for the respective individual client; and
adding the financial transaction to the compilation of transactions for the respective individual client that performed the financial transaction, thereby compiling separate compilations of transactions for one or more of the individual clients from the financial transaction data, each compilation of transactions comprising financial transaction data related to a respective individual client;
comparing, by the one or more computer processors, for each compilation of transactions, external financial transactions in the compilation of transactions for the respective individual client with at least one screening criterion for detecting a suspicious pattern of financial transaction activity by each respective individual client; and
determining, by the one or more computer processors and based on the comparison, whether the compilation of transactions for the respective individual client includes financial transactions that match the at least one screening criterion; and
reporting, by the one or more computer processors, each compilation of transactions for each respective individual client that satisfies the at least one screening criterion.
11. The method of claim 10, wherein the list of excluded internal transaction types includes systematic redemption transactions, dealer account transactions, omnibus account transactions, dividend transactions, capital gain transactions, and redemption transactions due to death of an account holder.
12. The method of claim 10, wherein at least some of the compilations of transactions each include a plurality of financial transactions, and the plurality of financial transactions collectively relate to a plurality of accounts related to the respective individual client for the each compilation of transactions.
13. The method of claim 10, wherein the at least one screening criterion includes one or both of a criterion based on (a) an aggregate monetary amount of all external financial transactions in a respective compilation of transactions for the individual client, and (b) an aggregate number of all external financial transactions within the screening time interval in the respective compilation of transactions for the individual client.
14. The method of claim 10, further comprising excluding, by the one or more computer processors, selected external financial transactions.
15. The method of claim 10, wherein reporting each compilation of transactions for each respective individual client that satisfies the at least one screening criterion comprises transmitting, by a communications device, a monitoring report including each reported compilation of transactions to an analyst computer for review.
16. The method of claim 10, wherein the at least one screening criterion comprises at least one screening for detecting a suspicious pattern of financial transaction activity by each respective individual client during a screening time interval.
17. An account administration server computer system configured to handle financial transactions and manage records relating to financial accounts issued by a financial institution, comprising:
a database system storing financial transaction data;
an analyst computer system; and
a transaction monitoring server computer system for detecting questionable financial transactions by individual clients, the transaction monitoring server computer system in communication with the account administration server computer system and the analyst computer system, and comprising:
one or more data storage devices storing a list of excluded internal transaction types and financial transaction data for financial transaction by the individual clients;
one or more computer processors in communication with the one or more data storage devices;
a communications device in communication with the one or more computer processors and the one or more data storage devices; and
a memory, coupled to the one or more computer processors, storing program instructions which are operative with the one or more computer processors to:
receive data indicative of financial transactions from the database system of the account administration server computer;
compare each of the financial transactions to the list of excluded internal transaction types, wherein the list includes systematic redemption transactions;
determine, for each of the financial transactions, based on the comparison, whether the financial transaction is an excluded internal transaction;
responsive to a determination that the financial transaction is an excluded internal transaction, exclude the financial transaction from additional screening;
responsive to a determination that the financial transaction is not an excluded internal transaction:
determine whether a compilation of transactions already exists for transactions of the respective individual client;
responsive to a negative determination that the compilation of transactions already exists for the respective individual client, create the compilation of transactions for the respective individual client; and
add the financial transaction to the compilation of transactions for the respective individual client that performed the financial transaction, thereby compiling separate compilations of transactions for one or more of the individual clients from the financial transaction data, each compilation of transactions comprising financial transaction data related to a respective individual client during a screening time interval;
compare, for each compilation of transactions, the financial transactions in the compilation of transactions for the respective individual client with at least one screening criteria for detecting a suspicious pattern of financial transaction activity by each respective individual client;
determine, based on the comparison, whether the compilation of transactions for the respective individual client includes questionable financial transactions that match the at least one screening criteria; and
responsive to a determination that a compilation of transactions matches the at least one screening criterion, adding the compilation of transactions to a monitoring report; and
output the monitoring report for each compilation of transactions for each respective individual client that satisfies the screening criteria to the analyst computer for review.
18. The computer system of claim 17, wherein the list of excluded internal transaction types stored in the one or more data storage devices further includes dealer account transactions, omnibus account transactions, dividend transactions, capital gain transactions, and redemption transactions due to death of an account holder.
19. The computer system of claim 18, wherein at least some of the compilation of transactions each include a plurality of financial transactions, and the plurality of financial transactions collectively relate to a plurality of accounts related to the respective individual client for the each compilation of transactions.
20. The system of claim 19, wherein the at least one screening criteria includes one or both of a criterion based on (a) an aggregate monetary amount of all external financial transactions in a respective compilation of transactions for the individual client, and (b) an aggregate number of all external financial transactions within the screening time interval in the respective compilation of transactions for the individual client.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A compound of the formula (I):
1464
wherein, X1 and X2 are independently selected from N, NR4, O or S, provided that if X1 is NR4, O or S, then X2 is N, or if X2 is NR4, O or S, then X2 is N, and both X1 and X2 are not N;
Y is O or S;
A1 is substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, or heteroarylarylalkyl;
A2 is substituted or unsubstituted heteroaryl;
R1 is O or H, and R2 is NR5 R6 or hydroxyl; or R1 is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy;
R4 is hydrogen, hydroxyl, alkylamino, dialkylamino or alkyl;
R5 and R6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; and
R7 is loweralkyl;
or a pharmaceutically acceptable salt, ester or prodrug thereof.
2. A compound of claim 1 wherein X is NR4.
3. A compound of claim 2 wherein R4 is hydrogen.
4. A compound of claim 2 wherein R4 is methyl.
5. A compound of claim 1 wherein Y is O.
6. A compound of claim 1 wherein A1 is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclocarbonylphenyl, heterocyclophenyl, heterocycloalkylphenyl, chlorophenyl, flourophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylflourophenyl, triflouromethylchlorophenyl, triflouromethylbromophenyl indenyl, 2,3-dihydroindenyl, tetralinyl, triflourophenyl, (triflouromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N-morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl, indolyl, 2,3-dihydroindolyl, 1-aceytl-2,3-dihydroindolyl, cycloheptyl, bicyclo2.2.1hept-2-yl, hydroxyphenyl, hydroxyalkylphenyl, pyrrolidinyl, pyrrolidin-1-yl, pyrrolidin-1-ylalkyl, 4-amino(imino)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, napthyl, benzophenone, anilinyl, anisolyl, quinolinyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-1-yl, piperidin-1-yl, piperidin-1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-1-yl, hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, 1,4-bipiperidin-1-yl, and (1,4-bipiperidin-1-ylcarbonyl)phenyl.
7. A compound of claim 1 wherein A2 is substituted or unsubstituted pyridyl.
8. A compound of claim 1 wherein R1 is O and the dashed line represents a single or double bond.
9. A compound of claim 1 wherein R2 is NR5R6, R5 is hydrogen and R6 is selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl.
10. A compound of claim 1 wherein R1 is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group.
11. A compound of claim 1 wherein R3 is loweralkoxy.
12. A compound of claim 11 wherein R3 is methoxy.
13. A compound of claim 1 wherein R4 is loweralkyl.
14. A compound of claim 13 wherein R4 is methyl.
15. The compound of claim 1 wherein R1 is O, R2 is NR5R6, R5 is H, and R6 is methyl.
16. A compound of the formula (II):
1465
wherein and Y is O or S;
A1 is substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, heteroarylarylalkyl;
A2 is substituted or unsubstituted heteroaryl;
R1 is O and R2 is NR5 R6; or R1 is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy;
R4 is hydrogen or loweralkyl;
R5 and R6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; or
a pharmaceutically acceptable salt, ester or prodrug thereof.
17. A compound of claim 16 wherein R4 is hydrogen.
18. A compound of claim 16 wherein R4 is methyl.
19. A compound of claim 16 wherein Y is O.
20. A compound of claim 16 wherein A1 is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclocarbonylphenyl, heterocyclophenyl, heterocycloalkylphenyl, chlorophenyl, flourophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylflourophenyl, triflouromethylchlorophenyl, triflouromethylbromophenyl indenyl, 2,3-dihydroindenyl, tetralinyl, triflourophenyl, (triflouromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N-morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl, indolyl, 2,3-dihydroindolyl, 1-aceytl-2,3-dihydroindolyl, cycloheptyl, bicyclo2.2.1hept-2-yl, hydroxyphenyl, hydroxyalkylphenyl, pyrrolidinyl, pyrrolidin-1-yl, pyrrolidin-1-ylalkyl, 4-amino(imino)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, napthyl, benzophenone, anilinyl, anisolyl, quinolinyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-1-yl, piperidin-1-yl, piperidin-1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-1-yl, hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, 1,4-bipiperidin-1-yl, and (1,4-bipiperidin-1-ylcarbonyl)phenyl.
21. A compound of claim 16 wherein A2 is substituted or unsubstituted pyridyl.
22. A compound of claim 16 wherein R1 is O and the dashed line represents a single or double bond.
23. A compound of claim 16 wherein R2 is NR5R6, R5 is hydrogen and R6 is selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl.
24. A compound of claim 16 wherein R1 is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group.
25. A compound of claim 16 wherein R1 is O, R2 is NR5R6, R5 is H, and R6 is methyl.
26. A compound of claim 16 wherein R3 is loweralkoxy.
27. A compound of claim 26 wherein R3 is methoxy.
28. A compound of claim 16 wherein R4 is loweralkyl.
29. A compound of claim 28 wherein R4 is methyl.
30. A compound of the formula (III):
1466
wherein X is NR4, O or S;
A1 is substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, heteroarylarylalkyl;
A2 is substituted or unsubstituted heteroaryl;
R1 is O and R2 is NR5 R6; or R1 is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy;
R4 is hydrogen or loweralkyl;
R5 and R6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; or
a pharmaceutically acceptable salt, ester or prodrug thereof.
31. A compound of claim 30 wherein X is NR4.
32. A compound of claim 31 wherein R4 is hydrogen.
33. A compound of claim 30 wherein R4 is methyl.
34. A compound of claim 30 wherein A1 is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclocarbonylphenyl, heterocyclophenyl, heterocycloalkylphenyl, chlorophenyl, flourophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylflourophenyl, triflouromethylchlorophenyl, triflouromethylbromophenyl indenyl, 2,3-dihydroindenyl, tetralinyl, triflourophenyl, (triflouromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N-morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl, indolyl, 2,3-dihydroindolyl, 1-aceytl-2,3-dihydroindolyl, cycloheptyl, bicyclo2.2.1hept-2-yl, hydroxyphenyl, hydroxyalkylphenyl, pyrrolidinyl, pyrrolidin-1-yl, pyrrolidin-1-ylalkyl, 4-amino(imino)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, napthyl, benzophenone, anilinyl, anisolyl, quinolinyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-1-yl, piperidin-1-yl, piperidin-1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-1-yl, hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, 1,4-bipiperidin-1-yl, and (1,4-bipiperidin-1-ylcarbonyl)phenyl.
35. A compound of claim 30 wherein A2 is substituted or unsubstituted pyridyl.
36. A compound of claim 30 wherein R1 is O and the dashed line represents a single or double bond.
37. A compound of claim 30 wherein R2 is NR5R6, R5 is hydrogen and R6 is selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl.
38. A compound of claim 30 wherein R1 is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group.
39. A compound of claim 30 wherein R3 is loweralkoxy.
40. A compound of claim 39 wherein R3 is methoxy.
41. A compound of claim 30 wherein R4 is loweralkyl.
42. A compound of claim 41 wherein R4 is methyl.
43. A compound of claim 30 wherein R1 is O, R2 is NR5R6, R5 is H, and R6 is methyl.
44. A compound of the formula (IV):
1467
wherein X is NR4, O or S;
Y is O or S;
A1 is substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, heteroarylarylalkyl;
R1 is O and R2 is NR5 R6; or R1 is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy;
R4 is hydrogen or loweralkyl;
R5 and R6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; or
a pharmaceutically acceptable salt, ester or prodrug thereof.
45. A compound of claim 44 wherein X is NR4.
46. A compound of claim 45 wherein R4 is hydrogen.
47. A compound of claim 45 wherein R4 is methyl.
48. A compound of claim 44 wherein Y is O.
49. A compound of claim 44 wherein A1 is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclocarbonylphenyl, heterocyclophenyl, heterocycloalkylphenyl, chlorophenyl, flourophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylflourophenyl, triflouromethylchlorophenyl, triflouromethylbromophenyl indenyl, 2,3-dihydroindenyl, tetralinyl, triflourophenyl, (triflouromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N-morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl, indolyl, 2,3-dihydroindolyl, 1-aceytl-2,3-dihydroindolyl, cycloheptyl, bicyclo2.2.1hept-2-yl, hydroxyphenyl, hydroxyalkylphenyl, pyrrolidinyl, pyrrolidin-1-yl, pyrrolidin-1-ylalkyl, 4-amino(imino)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, napthyl, benzophenone, anilinyl, anisolyl, quinolinyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-1-yl, piperidin-1-yl, piperidin-1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-1-yl, hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, 1,4-bipiperidin-1-yl, and (1,4-bipiperidin-1-ylcarbonyl)phenyl.
50. A compound of claim 44 wherein R1 is O and the dashed line represents a single or double bond.
51. A compound of claim 44 wherein R2 is NR5R6, R5 is hydrogen and R6 is selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl.
52. A compound of claim 44 wherein R1 is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group.
53. A compound of claim 44 wherein R3 is loweralkoxy.
54. A compound of claim 53 wherein R3 is methoxy.
55. A compound of claim 44 wherein R4 is loweralkyl.
56. A compound of claim 55 wherein R4 is methyl.
57. A compound of claim 44 wherein R1 is O, R2 is NR5R6, R5 is H, and R6 is methyl.
58. A compound of the formula (V):
1468
wherein X is NR4, O or S;
A1 is substituted or unsubstituted cycloalkyl, heterocycloalkyl, aryl, polycyclic aryl, polycyclic arylalkyl, heteroaryl, biaryl, heteroarylaryl, heteroarylheteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, biarylalkyl, heteroarylarylalkyl;
R1 is O and R2 is NR5 R6; or R1 is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group; wherein, the dashed line represents a single or double bond;
R3 is hydrogen, halogen, loweralkyl, or loweralkoxy;
R4 is hydrogen or loweralkyl;
R5 and R6 are independently selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl; or R5 and R6 are taken together to form substituted or unsubstituted heterocyclo or heteroaryl; or
a pharmaceutically acceptable salt, ester or prodrug thereof.
59. A compound of claim 58 wherein X is NR4.
60. A compound of claim 59 wherein R4 is hydrogen.
61. A compound of claim 59 wherein R4 is methyl.
62. A compound of claim 58 wherein A1 is selected from the group consisting of substituted or unsubstituted phenyl, pyridyl, pyrimidinyl, phenylalkyl, pyridylalkyl, pyrimidinylalkyl, heterocyclocarbonylphenyl, heterocyclophenyl, heterocycloalkylphenyl, chlorophenyl, flourophenyl, bromophenyl, iodophenyl, dihalophenyl, nitrophenyl, 4-bromophenyl, 4-chlorophenyl, alkylbenzoate, alkoxyphenyl, dialkoxyphenyl, dialkylphenyl, trialkylphenyl, thiophene, thiophene-2-carboxylate, alkylthiophenyl, trifluoromethylphenyl, acetylphenyl, sulfamoylphenyl, biphenyl, cyclohexylphenyl, phenyloxyphenyl, dialkylaminophenyl, alkylbromophenyl, alkylchlorophenyl, alkylflourophenyl, triflouromethylchlorophenyl, triflouromethylbromophenyl indenyl, 2,3-dihydroindenyl, tetralinyl, triflourophenyl, (triflouromethyl)thiophenyl, alkoxybiphenyl, morpholinyl, N-piperazinyl, N-morpholinylalkyl, piperazinylalkyl, cyclohexylalkyl, indolyl, 2,3-dihydroindolyl, 1-aceytl-2,3-dihydroindolyl, cycloheptyl, bicyclo2.2.1hept-2-yl, hydroxyphenyl, hydroxyalkylphenyl, pyrrolidinyl, pyrrolidin-1-yl, pyrrolidin-1-ylalkyl, 4-amino(imino)methylphenyl, isoxazolyl, indazolyl, adamantyl, bicyclohexyl, quinuclidinyl, imidazolyl, benzimidazolyl, imidazolylphenyl, phenylimidazolyl, pthalamido, napthyl, benzophenone, anilinyl, anisolyl, quinolinyl, quinolinonyl, phenylsulfonyl, phenylalkylsulfonyl, 9H-flouren-1-yl, piperidin-1-yl, piperidin-1-ylalkyl, cyclopropyl, cyclopropylalkyl, pyrimidin-5-ylphenyl, quinolidinylphenyl, furanyl, furanylphenyl, N-methylpiperidin-4-yl, pyrrolidin-4-ylpyridinyl, 4-diazepan-1-yl, hydroxypyrrolidn-1-yl, dialkylaminopyrrolidin-1-yl, 1,4-bipiperidin-1-yl, and (1,4-bipiperidin-1-ylcarbonyl)phenyl.
63. A compound of claim 58 wherein R1 is O and the dashed line represents a single or double bond.
64. A compound of claim 58 wherein R2 is NR5R6, R5 is hydrogen and R6 is selected from hydrogen, and substituted or unsubstituted alkyl, alkoxyalkyl, aminoalkyl, amidoalkyl, acyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxyalkylheterocyclo, and heteroarylalkyl.
65. A compound of claim 58 wherein R1 is taken together with R2 to form a substituted or unsubstituted heterocycloalkyl or heteroaryl group.
66. A compound of claim 58 wherein R3 is loweralkoxy.
67. A compound of claim 66 wherein R3 is methoxy.
68. A compound of claim 58 wherein R4 is loweralkyl.
69. A compound of claim 68 wherein R4 is methyl.
70. A compound of claim 58 wherein R1 is O, R2 is NR5R6, R5 is H, and R6 is methyl.
71. A composition comprising an amount of a compound of claims 1, 16, 30, 44, or 58 effective to inhibit Raf activity in a human or animal subject when administered thereto, together with a pharmaceutically acceptable carrier.
72. A composition of claim 71 which further comprises at least one additional agent for the treatment of cancer.
73. A composition of claim 72 in which the at least one additional agent for the treatment of cancer is selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.
74. A method of inhibiting Raf kinase activity in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of claims 1, 16, 30, 44 or 58 effective to inhibit Raf kinase activity in the human or animal subject.
75. A method for treating a cancer disorder in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of claims 1, 16, 30, 44 or 58 effective to inhibit Raf kinase activity in the human or animal subject.
76. A method of claim 75 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer.
77. A method of claim 76 in which the at least one additional agent for the treatment of cancer is selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.
78. A method for treating a hormone dependent cancer disorder in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of claims 1, 16, 30, 44 or 58 effective to inhibit Raf kinase activity in the human or animal subject.
79. A method of claim 78 wherein the hormone dependent cancer is breast cancer or prostate cancer.
80. A method of claim 78 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer.
81. A method of claim 80 in which the at least one additional agent for the treatment of cancer is selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.
82. A method for treating a hematological cancer disorder in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of claims 1, 16, 30, 44 or 58 effective to inhibit Raf kinase activity in the human or animal subject.
83. A method of claim 82 which further comprises administering to the human or animal subject at least one additional agent for the treatment of cancer.
84. A method of claim 83 in which the at least one additional agent for the treatment of cancer is selected from irinotecan, topotecan, gemcitabine, 5-fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophospharmide, vinca alkaloids, imatinib, anthracyclines, rituximab and trastuzumab.
85. A compound of claims 1, 16, 30, 44 or 58 for use in the treatment of cancer.
86. Use of a compound of claims 1, 16, 30, 44 or 58 in the manufacture of a medicament for the treatment of cancer.